Evaluating protein-protein interaction (PPI) networks for diseases pathway, target discovery, and drug-design using 'In silico pharmacology'

Current Protein and Peptide Science

Volumn 15, Issue 6, 2014, Pages 561-571

  Chakraborty, Chiranjib ^a,b   Priya Doss C, George ^c   Chen, Luonan ^d,e   Zhu, Hailong ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b GALGOTIAS UNIVERSITY   (India)

^c VIT UNIVERSITY   (India)

^d Chinese Academy of Sciences   (China)

^e INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

Author keywords

Drug discovery; PPI network

Indexed keywords

ABC TRANSPORTER A1; ACETYLCHOLINESTERASE; ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN; BETA CATENIN; CYCLIC NUCLEOTIDE; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; OROSOMUCOID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE III; PROTEIN NR1 1A; PROTEIN NR1 1B; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; SPLEEN EXONUCLEASE; SREBP CLEAVAGE ACTIVATING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG; PROTEIN;

ATOMIC FORCE MICROSCOPY; BIOLOGY; CELL COMPONENT; CLUSTER COEFFICIENT; COMPUTER MODEL; CRYOELECTRON MICROSCOPY; DEGREE CENTRALITY; DEGREE DISTRIBUTION; DRUG DESIGN; DRUG TARGETING; FLUORESCENCE MICROSCOPY; GRAPH THEORY; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; HUMAN; K NEAREST NEIGHBOR; LIPID HOMEOSTASIS; NODE DISTANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARAMETERS; PROTEIN DATABASE; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN PROTEIN NETWORK; PROTEIN STRUCTURE; PROTEOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THEORY; WNT SIGNALING PATHWAY; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION; ANIMAL; CHEMISTRY; COMPUTER AIDED DESIGN; DRUG DEVELOPMENT; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROTEIN ANALYSIS; ARTICLE; DATA BASE; HUNTINGTON CHOREA; INFECTION; INFLAMMATION; INSULIN RESISTANCE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DNA INTERACTION;

ANIMALS; COMPUTER-AIDED DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; PROTEINS;

EID: 84906897091     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203715666140724090153     Document Type: Review

References (181)

1. Stang, P.E.; Pham, S.V.; Kinchen, K.; Raff, S.B.; Mussen, F.; Gondek, K. The identification of benefit in medical intervention: an overview and suggestions for process. Am. J. Ther., 2000 15 (5), 495-503.
2. Rishton, G.M. Natural products as a robust source of new drugs and drug leads: past successes and Present day issues. Am. J. Cardiol., 2008 101, 43D-49D.
3. Pan, S.Y.; Pan, S.; Yu, Z.L.; Ma, D.L.; Chen, S.B.; Fong, W.F.; Han, Y.F.; Ko, K.M. New perspectives on innovative drug discovery: an overview. J. Pharm. Pharm. Sci., 2010 13 (3), 450-457.
4. Chakraborty, C. From editor desk: Current changing scenario of biotechnology and biochemistry advances in biochemistry and biotechnology (Vol.1) Daya Publishing House, Delhi, India, 2005, p. 1-9.
5. Drews, J. Drug discovery: a historical perspective. Science, 2000 287 (5460), 1960-1964.
6. Natalie, M.; Margino, S.; Erik, H.; Annelieke, P.; Geert, V.; Philippe, V. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. Toxicol. In vitro, 2009 23 (2), 217-226.
7. Chakraborty, C.; Hsu, C.H.; Wen, Z.H.; Lin, C.S. Recent advances of fluorescent technologies for drug discovery and development. Curr. Pharm. Des., 2009 15 (30), 3552-3570.
8. Collins, L.A.; Torrero, M.N.; Franzblau, S.G. A green fluorescent protein (GFP) microplate assay (GFPMA) for the high throughput screening of compounds against Mycobacterium tuberculosis was developed. Antimicrob. Agents Chemother., 1998 42, 344-347.
9. DiMasi, J.A.; Hansen, R.W.; Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health Econ., 2003 22, 151-185.
10. Gassmann, O.; Reepmeyer, G.; Von Zedtwitz, M. Leading pharmaceutical innovation: trends and drivers for growth in the pharmaceutical industry. 2004, Springer-Verlag, 178 pages.
11. Augen, J. The evolving role of information technology in the drug discovery process. Drug Discov. Today, 2002 7 (5), 315-323.
12. Corsini, A.; Bellosta, S.; Baetta, R.; Fumagalli, R.; Paoletti, R.; Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther., 1999 84, 413-428.
13. Corsini, A.; Maggi, F.M.; Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res., 1995 31, 9-27.
14. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; et al. Studies of the HER-2/neuproto-oncogene in human breast and ovarian cancer. Science, 1989 244, 707-712.
15. Ekins, S.; Mestres, J.; Testa, B. In silico pharmacology for drug discovery: applications to targets and beyond. Br. J. Pharmacol., 2007 152 (1), 21-37.
16. Ma, S.; Feng, C.; Zhang, X.; Dai, G.; Li, C.; Cheng, X.; Liu, P.; Ju, W.; Yu, H. The multi-target capabilities of the compounds in a TCM used to treat sepsis and their in silico pharmacology. Complement Ther. Med., 2013 21 (1), 35-41.
17. Chakraborty, C.; Roy, S.S.; Hsu, M.J.; Agoramoorthy, G. Landscape mapping of functional proteins in insulin signal transduction and insulin resistance: A network based protein-protein interaction analysis. PLoS ONE, 2001 6 (1), e16388.
18. Chakraborty, C.; Roy, S.S.; Hsu, C.H.; Wen, Z.H.; Lin, C.S. Network building of proteins in a biochemical pathway: a computational biology related model for target discovery and drug-design. Curr. Bioinformatics, 2010 5 (4), 290-295.
19. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov., 2005 4 (3), 206-220.
20. Butler, M.S. Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep., 2008 25, 475-516.
21. Harvey, A.L. Natural products in drug discovery. Drug Discov. Today, 2008 13 (19-20), 894-901.
22. Schofield, P.N.; Gkoutos, G.V.; Gruenberger, M.; Sundberg, J.P.; Hancock, J.M. Phenotype ontologies for mouse and man: bridging the semantic gap. Dis. Model Mech., 2010 3 (5-6), 281-289.
23. Kell, D.B. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J., 2013 280 (23), 5957-5980.
24. Drews, J. Stategic trends in the drug industry. Drug Discov. Today, 2003 8, 411-420.
25. Augen, J. The evolving role of information technology in the drug discovery process. Drug Discov. Today, 2002 7, 315-323.
26. Xu, J.; Hagler, A. Chemoinformatics and drug discovery. Molecules, 2002 7 (8), 566-600.
27. Patwardhan, B.; Vaidya, A. D.; Chorghade, M.; Joshi, S. P. Reverse pharmacology and systems approaches for drug discovery and development. Curr. Bioact. Compd., 2008 4 (4), 201-212.
28. Broder, S.; Venter, J.C. Sequencing the entire genomes of freeliving organisms: the foundation of pharmacology in the new millennium. Ann. Rev. Pharmacol. Toxicol., 2000 40, 97-132.
29. Chanda, S.K.; Caldwell, J.S. Fulfilling the promise: drug discovery in the postgenomic era. Drug Discov. Today, 2003 8 (4), 168-174.
30. Davidov, E.; Holland, J.; Marple, E.; Naylor, S. Advancing drug discovery through systems biology. Drug Discov. Today, 2003 8 (4), 175-183.
31. Ji, H.F.; Li, X.J.; Zhang, H.Y. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep., 2009, 10(3), 194-200.
32. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multitarget drugs: the network approach might help drug design. Trends Pharmacol. Sci., 2005 26, 178-182.
33. Dancey, J.E.; Chen, H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov., 2006 5, 649-659.
34. Zimmermann, G. R.; Lehár, J.; Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today, 2007 12, 34-42.
35. Takenaka, T. Classical vs reverse pharmacology in drug discovery. BJU Int., 2001 88 (2), 7-10.
36. Rask-Andersen, M.; Almén, M. S.; Schiöth, H. B. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov., 2011 10 (8), 579-590.
37. Smith, C. Hitting the target. Nature, 2003 422, 341-347.
38. Yildirim, M.A.; Goh, K.-L.; Cusick, M.E.; Barabási, A.-L.; Vidal, M. Drug-target network. Nat. Biotechnol., 2007 25 (10), 1119-1126
39. Congreve, M.; Murray, C.W.; Blundell, T.L. Structural biology and drug discovery. Drug Discov. Today, 2005 10 (13), 895-907.
40. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discov., 2006, 5, 993-996.
41. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov., 2002 1, 727-730.
42. Imming, P.; Sinning, C.; Meyer, A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov., 2006 5, 821-834.
43. Overington, J.P.; Bissan, A.; Hopkins, A. How many drug targets are there? Nat. Rev. Drug Discov., 2006, 5, 993-996.
44. Russ, A.P.; Lampel, S. The druggable genome: an update. Drug Discov. Today, 2005 10, 1607-1610.
45. Bairoch, A. The ENZYME database in 2000. Nucleic Acids Res., 2000 28 (1), 304-305.
46. Agarwal, P.K. Role of protein dynamics in reaction rate enhancement by enzymes. J. Am. Chem. Soc., 2005 127 (43), 15248-15256.
47. Neefjes, J.; Dantuma, N.P. Fluorescent probes for proteolysis: tools for drug discovery. Nat. Rev. Drug Discov., 2004 3, 58-69.
48. Falasca, M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr. Pharm. Des., 2010 16 (12), 1410-1416.
49. Turk, B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov., 2006 5 (9), 785-799.
50. Drag, M.; Salvesen, G.S. Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov., 2010 9 (9), 690-701.
51. Guthikonda, S.; Lev, E.I.; Patel, R.; DeLao, T.; Bergeron, A.L.; Dong, J.F.; Kleiman, N.S. Reticulated platelets and uninhibited COX_1 and COX_2 decrease the antiplatelet effects of aspirin. J. Thromb. Haemost., 2007 5 (3), 490-496.
52. Garcia-Garcia, F.J.; Mullol, J.; Perez-Gonzalez, M.; Pujols, L.; Alobid, I.; Roca-Ferrer, J.; Picado, C. Signal Transduction Pathways (MAPKs, NF-_B, and C/EBP) Regulating COX-2 Expression in Nasal Fibroblasts from Asthma Patients with Aspirin Intolerance. PloS one, 2012 7 (12), e51281.
53. Hughes, J.P.; Rees, S.; Kalindjian, S.B.; Philpott, K.L. Principles of early drug discovery. Br. J. Pharmacol., 2011 162 (6), 1239-1249.
54. Barabasi, A.L.; Oltvai, Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet., 2004 5, 101-113.
55. Han, J.D.; Bertin, N.; Hao, T.; Goldberg, D.S.; Berriz, G.F.; Zhang, L.V.; Dupuy, D.; Walhout, A.J.; Cusick, M.E.; Roth, F.P.; Vidal, M. Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature, 2004 430, 88-93.
56. Jeong, H.; Mason, S.; Barabasi, A.-L.; Oltvai, Z. Lethality and centrality in protein networks. Nature, 2001 411, 41-42.
57. Goh, K.I.; Cusick, M.E.; Valle, D.; Childs, B.; Vidal, M.; Barabási, A.L. The human disease network. Proc. Natl. Acad. Sci. U.S.A., 2007 104, 8685-8690.
58. Bhalla, U.S.; Iyengar, R. Emergent properties of networks of biological signaling pathways. Science, 1999 283 (5400), 381-387.
59. Rask-Andersen, M.; Almen, M.S.; Schioth, H.B. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov., 2011 10 (8), 579-590.
60. Yildirim, M.A.; Goh, K.I.; Cusick, M.E.; Barabasi, A.L.; Vidal, M. Drug-target network. Nat. Biotech., 2007 25, 1119-1126.
61. Jeong, H.; Mason, S.P.; Barabási, A.L.; Oltvai, Z.N. Lethality and centrality in protein networks. Nature, 2001 411 (6833), 41-42.
62. Milo, R.; Shen-Orr, S.; Itzkovitz, S.; Kashtan, N.; Chklovskii, D.; Alon, U. Network motifs: simple building blocks of complex networks. Science Signaling, 2002 298 (5594), 824.
63. Viswanathan, G.A.; Seto, J.; Patil, S.; Nudelman, G.; Sealfon, S.C. Getting started in biological pathway construction and analysis. PLoS Comput. Biol., 2008, 4(2): e16.
64. Vidal, M. Interactome modeling. FEBS Lett., 2005, 579, 1834-1838.
65. Brehme, M.; Vidal, M. A global protein-lipid interactome map. Mol. Syst. Biol., 2010 6, 6443.
66. Tarassov, K.; Messier, V.; Landry, C.R.; Radinovic, S.; Serna Molina, M.M.; Shames, I.; Malitskaya, Y.; Vogel, J.; Bussey, H.; Michnick, S.W. An in vivo map of the yeast protein interactome. Science, 2008 320 (5882), 1465-1470.
67. Vidal, M. A unifying view of 21st century systems biology. FEBS Lett., 2009 583 (24), 3891-3894.
68. Fromont-Racine, M.; Rain, J.C.; Legrain, P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat. Genet., 1997 16 (3), 277-282.
69. Vidal, M. The reverse two-hybrid system. In: Bartels P, Fields S, editors. The Yeast Two-Hybrid System. New York: Oxford University Press, 1997, pp. 109-147.
70. Dreze, M.; Monachello, D.; Lurin, C.; Cusick, M.E.; Hill, D.E.; Vidal, M.; Braun, P. High-quality binary interactome mapping. Methods Enzymol., 2010 470, 281-315.
71. Rajapakse, I.; Scalzo, D.; Tapscott, S.J.; Kosak, S.T.; Groudine, M. Networking the nucleus. Mol. Syst. Biol., 2010 6, 395.
72. Cowan, N.J.; Chastain, E.J.; Vilhena, D.A.; Freudenberg, J.S.; Bergstrom, C.T. Nodal Dynamics, Not Degree Distributions, Determine the Structural Controllability of Complex Networks. PLoS ONE, 2012 7 (6), e38398.
73. Duan, Z.; Chen, G.; Huang, L. Complex network synchronizability: Analysis and control. Phys. Rev. E., 2007 76, 056103.
74. Porfiri, M.; di Bernardo, M. Criteria for global pinningcontrollability of complex networks. Automatica, 2008 44, 3100-3106.
75. Peregrín-Alvarez, J.M.; Xiong, X.; Su, C.; Parkinson, J. The Modular Organization of Protein Interactions in Escherichia coli. PLoS Comput. Biol., 2009 5 (10), e1000523.
76. Jeong, H.; Mason, S.P.; Barabási, A.L.; Oltvai, Z.N. Lethality and centrality in protein networks. Nature, 2001 411, 41-42.
77. Nikolsky, Y.; Nikolskaya, T.; Bugrim, A. Biological networks and analysis of experimental data in drug discovery. Drug Discov. Today, 2005 10 (9), 653-662.
78. Shen, R.; Goonesekere, N.C.; Guda, C. Mining functional subgraphs from cancer protein-protein interaction networks. BMC Syst. Biol., 2012 6 (3), S2.
79. Bullmore, E.; Sporns, O. Review Complex brain networks: graph theoretical analysis of structural and functional systems. Nat. Rev. Neurosci., 2009 10 (3), 186-198.
80. Andrews, M.; Zhang, L. Hardness of the undirected edge-disjoint paths problem. In Proceedings of the thirty-seventh annual ACM symposium on Theory of computing, 2005, pp. 276-283.
81. Krogan, N.J.; Cagney, G.; Yu, H.; Zhong, G.; Guo, X.; Ignatchenko, A.; Li, J.; Pu, S.; Datta, N.; Tikuisis, A.P.; et al. Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature, 2006, 440(7084), 637-643.
82. Ewing, R.M.; Chu, P.; Elisma, F.; Li, H.; Taylor, P.; Climie, S.; McBroom-Cerajewski, L.; Robinson, M.D.; O'Connor, L.; Li, M.; et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol., 2007 3, 89.
83. Barabási, A.L.; Albert, R. Emergence of scaling in random networks. Science, 1999 286, 509-512.
84. Yoon, J.; Blumer, A.; Lee, K. An algorithm for modularity analysis of directed and weighted biological networks based on edgebetweenness centrality. Bioinformatics, 2006 22, 3106-3108.
85. Barabási, A.-L.; Albert, R. Emergence of Scaling in Random Networks. Science, 1999 286, 509.
86. Jeong, H.; Tombor, B.; Albert, R.; Oltvai, Z.N.; Barabási, A.L. The large-scale organization of metabolic networks. Nature, 2000 407, 651.
87. Milo, R.; Shen-Orr, S.; Itzkovitz, S.; Kashtan, N.; Chklovskii, D.; Alon, U. Network motifs: simple building blocks of complex networks. Science Signaling, 2002 298 (5594), 824.
88. Chang, X.; Xu T.; Li, Y.; Wang K. Dynamic modular architecture of protein-protein interaction networks beyond the dichotomy of 'date' and 'party' hubs. Sci. Rep., 2013 3, 1691.
89. Dong, J.; Horvath, S. Understanding network concepts in modules. BMC Syst. Biol., 2007 1, 24.
90. Barabási, A.L.; Oltvai, Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet., 2004 5, 101-113.
91. Hanneman, R.A.; Riddle, M. Introduction to Social Network Methods. (University of California), 2005.
92. Watts, D.J.; Strogatz, S.H. Collective dynamics of 'small-world' networks. Nature, 1998 393, 440-442.
93. Newman, M.E. The structure and function of complex networks. SIAM Rev., 2003 45 (2), 167-256.
94. Palla, G.; Derényi, I.; Farkas, I.; Vicsek, T. Uncovering the overlapping community structure of complex networks in nature and society. Nature, 2005 435 (7043), 814-818.
95. Maslov, S.; Sneppen, K. Specificity and stability in topology of protein networks. Science, 2002 296, 910-913.
96. Jeong, H.; Mason, S.P.; Barabási, A.L.; Oltvai, Z.N. Lethality and centrality in protein networks. Nature, 2001 411 (6833), 41-42.
97. Zotenko, E.; Mestre, J.; O'Leary, D.P.; Przytycka, T.M. Why Do Hubs in the Yeast Protein Interaction Network Tend To Be Essential: Reexamining the Connection between the Network Topology and Essentiality. PLoS Comput. Biol., 2008 4 (8), e1000140.
98. Gonzalez, M.W.; Kann, M.G. Chapter 4: Protein Interactions and Disease. PLoS Comput. Biol., 2012 8 (12), e1002819.
99. Barabasi, A.L.; Oltvai, Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet., 2004 5, 101-113.
100. Grindrod, P.; Kibble, M. Review of uses of network and graph theory concepts within proteomics. Expert Rev. Proteomics, 2004 1, 229-238.
101. Chuang, H.Y.; Lee, E.; Liu, Y.T.; Lee, D.; Ideker, T. Networkbased classification of breast cancer metastasis. Mol. Syst. Biol., 2007 3, 140.
102. Ideker, T.; Ozier, O.; Schwikowski, B.; Siegel, A.F. Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics, 2002 18 (1), S233-S240.
103. Hallock, P.; Thomas, M.A. Integrating the Alzheimer's disease proteome and transcriptome: a comprehensive network model of a complex disease. OMICS, 2012 16, 37-49.
104. Milo, R.; Shen-Orr, S.; Itzkovitz, S.; Kashtan, N.; Chklovskii, D.; Alon, U. Network motifs: simple building blocks of complex networks. Science, 2002 298, 824-827.
105. Goehler, H.; Lalowski, M.; Stelzl, U.; Waelter, S.; Stroedicke M, et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell, 2004 15, 853-865.
106. Duennwald, M.L.; Jagadish, S.; Giorgini, F.; Muchowski, P.J.; Lindquist, S. A network of protein interactions determines polyglutamine toxicity. Proc. Natl. Acad. Sci. U. S. A., 2006 103, 11051-11056.
107. Giorgini, F.; Muchowski, P.J. Connecting the dots in Huntington's disease with protein interaction networks. Genome Biol., 2005 6, 210.
108. Brauch, H.; Kishida, T.; Glavac, D.; Chen, F.; Pausch, F.; et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum. Genet., 1995 95, 551-556.
109. Ohh, M.; Park, C.W.;[Ivan, M.; Hoffman, M.A.; Kim, T.Y.; et al. Ubiquitination of hypoxiainducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol., 2000 2, 423-427.
110. Taylor, I.W.; Linding, R.; Warde-Farley, D.; Liu, Y.; Pesquita, C.; et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol., 2009 27, 199-204.
111. Wuchty, S. Computational prediction of host-parasite protein interactions between P. falciparum and H. sapiens. PLoS ONE, 2011, 6(11), e26960.
112. Doolittle, J.M.; Gomez, S.M. Structural similarity-based predictions of protein interactions between HIV-1 and Homo sapiens. Virol. J., 2010 7 (1), 82.
113. Doolittle, J.M.; Gomez, S.M. Mapping protein interactions between Dengue virus and its human and insect hosts. PLoS Negl. Trop. Dis., 2011 5 (2), e954.
114. Krishnadev, O.; Srinivasan, N. A data integration approach to predict ostpathogen protein-protein interactions: Application to recognize protein interactions between human and a malarial parasite. In Silico Biol., 2008 8 (3), 235-250.
115. Dyer, M.D.; Murali, T.M.; Sobral, B.W. Supervised learning and prediction of physical interactions between human and HIV proteins. Infect. Genet. Evol., 2011 11 (5), 917-923.
116. Krishnadev, O.; Srinivasan, N. Prediction of protein-protein interactions between human host and a pathogen and its application to three pathogenic bacteria. Int. J. Biol. Macromol., 2011 48, 613-619.
117. Tastan, O.; Qi, Y.; Carbonell, J.G.; Klein-Seetharaman, J. Prediction of interactions between HIV-1 and human proteins by information integration. Pac. Symp. Biocomput., 2009 14, 516-527.
118. Qi, Y.; Tastan, O.; Carbonell, J. G.; Klein-Seetharaman, J.; Weston, J. Semi-supervised multi-task learning for predicting interactions between HIV-1 and human proteins. Bioinformatics, 2010 26 (18), i645-i652.
119. Rain, J.C.; Selig, L.; De Reuse, H.; Battaglia, V.; Reverdy, C.; Simon, S.; Lenzen, G.; Petel, F.; Wojcik, J.; Schachter, V.; et al. The protein-protein interaction map of Helicobacter pylori. Nature, 2001 409, 211-215.
120. LaCount, D.J.; Vignali, M.; Chettier, R.; Phansalkar, A.; Bell, R.; Hesselberth, J.R.; Schoenfeld, L.W.; Ota, I.; Sahasrabudhe, S.; Kurschner, C.; et al. A protein interaction network of the malaria parasite Plasmodium falciparum. Nature, 2005 438, 103-107.
121. Suthram, S.; Sittler, T.; Ideker, T. The Plasmodium protein network diverges from those of other eukaryotes. Nature, 2005 438, 108-112.
122. Uetz, P.; Dong, Y.A.; Zeretzke, C.; Atzler, C.; Baiker, A.; Berger, B.; Rajagopala, S.V.; Roupelieva, M.; Rose, D.; Fossum, E.; et al. Herpesviral protein networks and their interaction with the human proteome. Science, 2006 311, 239-242.
123. Calderwood, M.A.; Venkatesan, K.; Xing, L.; Chase, M.R.; Vazquez, A.; Holthaus, A.M.; Ewence, A.E.; Li, N.; Hirozane-Kishikawa, T.; Hill, D.E.; et al. Epstein-Barr virus and virus human protein interaction maps. Proc. Natl. Acad. Sci., 2007 104, 7606-7611.
124. Uversky, V.; Longhi, S. Instrumental analysis of intrinsically disordered proteins: assessing structure and conformation (Vol. 3). Wiley, 2011.
125. Henzler-Wildman, K.; Kern, D. Dynamic personalities of proteins. Nature, 2007 450 (7172), 964-972.
126. Schlichting, I.; Berendzen, J.; Chu, K.; Stock, A.M.; Maves, S.A.; Benson, D.E.; Sweet, R.M.; Ringe, D.; Petsko, G.A.; Sligar, S.G. The catalytic pathway of cytochrome P450cam at atomic resolution. Science, 2000 287, 1615-1622.
127. Bourgeois, D.; Royant, A. Advances in kinetic protein crystallography. Curr. Opin. Struct. Biol., 2005 15, 538-547.
128. Englander, S.W. Hydrogen exchange and mass spectrometry: a historical perspective. J. Am. Soc. Mass Spectrom., 2006 17, 1481-1489.
129. Ito, T.; Chiba, T.; Ozawa, R.; Yoshida, M.; Hattori, M.; Sakaki, Y. A comprehensive two-hybrid analysis to explore the yeast protein interactome. Proc. Natl. Acad. Sci. U.S.A., 2001 98, 4569-4574.
130. Rual, J.F.; Venkatesan, K.; Hao, T.; Hirozane-Kishikawa, T.; Dricot, A.; Li, N.; Berriz, G.F.; Gibbons, F.D.; Dreze, M.; Ayivi-Guedehoussou, N.; et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature, 2005 437, 1173-1178.
131. Stelzl, U.; Worm, U.; Lalowski, M.; Haenig, C.; Brembeck, F.H.; Goehler, H.; Stroedicke, M.; Zenkner, M.; Schoenherr, A.; Koeppen, S.; et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell, 2005 122, 957-968.
132. Ewing, R.M.; Chu, P.; Elisma, F.; Li, H.; Taylor, P.; Climie, S.; McBroom-Cerajewski, L.; Robinson, M.D.; O'Connor, L.; Li, M.; et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol., 2007 3, 89.
133. Krogan, N.J.; Cagney, G.; Yu, H.; Zhong, G.; Guo, X.; et al. Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature, 2006 440, 637-643.
134. Spirin, V.; Mirny, L.A. Protein complexes and functional modules in molecular networks. Proc. Natl. Acad. Sci. U.S.A., 2003 100, 12123-12128.
135. Bandyopadhyay, S.; Sharan, R.; Ideker, T. Systematic identification of functional orthologs based on protein network comparison. Genome Res., 2006 16, 428-435.
136. Lee, H.; Tu, Z.; Deng, M.; Sun, F.; Chen, T. Diffusion kernel-based logistic regression models for protein function prediction. OMICS: A Journal of Integrative Biology, 2006 10, 40-55.
137. Yamada, T.; Kanehisa, M.; Goto, S. Extraction of phylogenetic network modules from the metabolic network. BMC Bioinformatics, 2006 7, 130.
138. Shoemaker, B.A.; Panchenko, A.R.; Bryant, S.H. Finding biologically relevant protein domain interactions: conserved binding mode analysis. Protein Sci., 2006 15, 352-361.
139. Sprinzak, E.; Margalit, H. Correlated sequence-signatures as markers of protein-protein interaction. J. Mol. Biol., 2001 311, 681-692.
140. Fraser, H.B.; Hirsh, A.E.; Wall, D.P.; Eisen, M.B. Coevolution of gene expression among interacting proteins. Proc. Natl. Acad. Sci. U.S.A., 2004 101, 9033-9038.
141. Kanaan, S.P.; Huang, C.; Wuchty, S.; Chen, D.Z.; Izaguirre, J.A. Inferring protein-protein interactions from multiple protein domain combinations. Methods Mol. Biol., 2009 541, 43-59.
142. Guimaraes, K.S.; Przytycka, T.M. Interrogating domain-domain interactions with parsimony based approaches. BMC Bioinformatics, 2008 9, 171.
143. Aittokallio, T.; Schwikowski, B. Graph-based methods for analysing networks in cell biology. Brief Bioinform., 2006 7 (3), 243-255.
144. Hayes, W.; Sun, K.; Przulj, N. Graphlet-based measures are suitable for biological network comparison. Bioinformatics, 2013 29 (4), 483-491.
145. Przulj, N. Biological network comparison using graphlet degree distribution. Bioinformatics, 2007 23, e177-e183.
146. Przulj, N.; Corneil, D.G.; Jurisica, I. Modeling interactome: scalefree or geometric? Bioinformatics, 2004, 20, 3508-3515.
147. Xenarios, I.; Rice, D. W.; Salwinski, L.; Baron, M. K.; Marcotte, E. M.; Eisenberg, D. DIP: The database of interacting proteins. Nucleic Acids Res., 2000 28 (1), 289-291.
148. Stark, C.; Breitkreutz, B.J.; Chatr-Aryamontri, A.; Boucher, L.; Oughtred, R.; Livstone, M.S.; Nixon, J.; Van Auken, K.; Wang, X.; Shi, X.; Reguly, T.; Rust, J.M.; Winter, A.; Dolinski, K.; Tyers, M. The BioGRID Interaction Database: 2011 update. Nucleic Acids Res., 2011 39, D698-D704.
149. Jensen, L.J.; Kuhn, M.; Stark, M.; Chaffron, S.; Creevey, C.; Muller, J.; Doerks, T.; Julien, P.; Roth, A.; Simonovic, M.; Bork, P.; von Mering, C. STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res., 2009 37, D412-D416.
150. Kamburov, A.; Pentchev, K.; Galicka, H.; Wierling, C.; Lehrach, H.; Herwig, R. ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res., 2011 39, D712-D717.
151. Frolkis, A.; Knox, C.; Lim, E.; Jewison, T.; Law, V.; Hau, D.D.; Liu, P.; Gautam, B.; Ly, S.; Guo, A.C.; Xia, J.; Liang, Y.; Shrivastava, S.; Wishart, D.S. SMPDB: The Small Molecule Pathway Database. Nucleic Acids Res., 2010 38, D480-D487.
152. Sengupta, U.; Ukil, S.; Dimitrova, N.; Agrawal, S. Expression-Based Network Biology Identifies Alteration in Key Regulatory Pathways of Type 2 Diabetes and Associated Risk/Complications. PLoS ONE, 2009 4 (12), e8100.
153. Goñi, J.; Esteban, F.J.; de Mendizábal, N.V.; Sepulcre, J.; Ardanza-Trevijano, S.; Agirrezabal, I.; Villoslada, P. A computational analysis of protein-protein interaction networks in neurodegenerative diseases. BMC Syst. Biol., 2008 2, 52.
154. Hert, J.; Keiser, M.J.; Irwin, J.J.; Oprea, T.I.; Shoichet, B.K. Quantifying the relationships among drug classes. J. Chem. Inf. Model, 2008 48, 755-765.
155. Golemis, E.A.; Tew, K.D.; Dadke, D. Protein interaction-targeted drug discovery: evaluating critical issues. Biotechniques, 2002 32 (3), 636-638.
156. Corada, M.; Nyqvist, D.; Orsenigo, F.; Caprini, A.; Giampietro, C.; Taketo, M.M.; Iruela-Arispe, M.L.; Adams, R.H.; Dejana, E. The Wnt/_-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev. Cell, 2010 18, 938-949.
157. Fu, L.; Zhang, C.; Zhang, L.Y.; Dong, S.S.; Lu, L.H.; Chen, J.; Dai, Y.; Li, Y.; Kong, K.L.; Kwong, D.L.; Guan, X.Y. Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/_-catenin signalling pathway. Gut, 2011 60, 1635-1643.
158. Logan, C.Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol, 2004, 20, 781-810.
159. Kemp, J.A.; McKernan, R.M. NMDA receptor pathways as drug targets. Nat. Neurosci., 2002 5, 1039-1042.
160. Kantrowitz, J.T.; Javitt, D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull., 2010, 83(3-4), 108.
161. Tremblay, A.M.; Dufour, C.R.; Ghahremani, M.; Reudelhuber, T.L.; Giguère, V. Physiological genomics identifies estrogenrelated receptor _ as a regulator of renal sodium and potassium homeostasis and the renin-angiotensin pathway. Mol. Endocrinol, 2010 24 (1), 22-32.
162. Spinale, F.G.; de Gasparo, M.; Whitebread, S., Hebbar, L.; Clair, M.J.; Melton, D.M.; Krombach, R.S.; Mukherjee, R.; Iannini, J.P.; O, S.J. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure I. Effects on left ventricular performance and neurohormonal systems. Circulation, 1997 96 (7), 2385-2396.
163. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 2009 8 (8), 627-644.
164. Hyman, B.T.; Strickland, D.; Rebeck, G.W. Role of the Lowdensity Lipoprotein Receptor-Related Protein in {beta}-Amyloid Metabolism and Alzheimer Disease. Arch. Neurol., 2000 57 (5), 646.
165. Khera, A.V.; Rader, D.J. Future therapeutic directions in reverse cholesterol transport. Curr. Atheroscler. Rep., 2010 12 (1), 73-81.
166. Sakai, J.; Rawson, R.B. The sterol regulatory element-binding protein pathway: control of lipid homeostasis through regulated intracellular transport. Curr. Opin. Lipidol., 2001 12 (3), 261-266.
167. Han, S.; Lone, M.A.; Schneiter, R.; Chang, A. Orm1 and Orm2 are conserved endoplasmic reticulum membrane proteins regulating lipid homeostasis and protein quality control. Proc. Nat. Acad. Sci., 2010, 107(13), 5851-5856.
168. Beavo, J.A.; Brunton, L.L. Cyclic nucleotide research-still expanding after half a century. Nat. Rev. Mol. Cell Biol., 2002, 3(9), 710-718.
169. Schwede, F.; Maronde, E.; Genieser, H.G.; Jastorff, B. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol. Ther., 2000 87 (2), 199-226.
170. Chakraborty, C. Biochemical and molecular basis of insulin resistance. Curr. Protein Pept. Sci., 2006, 7(2), 113-121.
171. Leney, S.E.; Tavaré, J.M. The molecular basis of insulin-stimulated glucose uptake: signalling, trafficking and potential drug targets. J. Endocrinol., 2009, 203(1), 1-18.
172. Ogata, H.; Goto, S.; Fujibuchi, W.; Kanehisa, M. Computation with the KEGG pathway database. Biosystems, 1998, 47(1), 119-128.
173. Le Novere, N.; Bornstein, B.; Broicher, A.; Courtot, M.; Donizelli, M.; Dharuri, H.; Li, L.; Sauro, H.; Schilstra, M.; Shapiro, B.; Snoep, J.L.; Hucka, M. BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems. Nucleic Acids Res., 2006 34, D689-D691.
174. Krupa, A.; Abhinandan, K.R.; Srinivasan, N. KinG: a database of protein kinases in genome. Nucleic Acids Res., 2004 32, 153-155.
175. Horn, F.; Bettler, E.; Oliveira, L.; Campagne, F.; Cohen, F.E.; Vriend, G. GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res., 2003 31, 294-297.
176. Goesmann, A.; Haubrock, M.; Meyer, F.; Kalinowski, J.; Giegerich, R. PathFinder: reconstruction and dynamic visualization of metabolic pathways. Bioinformatics, 2002, 18(1), 124-129.
177. Toyoda, T.; Mochizuki, Y.; Konagaya. A. GSCope: a clipped fisheye viewer effective for highly complicated biomolecular network graphs. Bioinformatics, 2003, 19, 437-438.
178. Matthews, L.; Gopinath, G.; Gillespie, M.; Caudy, M.; Croft, D.; de Bono, B.; Garapati, P.; Hemish, J.; Hermjakob, H.; Jassal, B.; Kanapin, A.; Lewis, S.; Mahajan, S.; May, B.; Schmidt, E.; Vastrik, I.; Wu, G.; Birney, E.; Stein, L.; D'Eustachio, P. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res., 2009 37, D619-D622.
179. Frolkis, A.; Knox, C.; Lim, E.; Jewison, T.; Law, V.; Hau, D.D.; Liu, P.; Gautam, B.; Ly, S.; Guo, A.C.; Xia, J.; Liang, Y.; Shrivastava, S.; Wishart, D.S. SMPDB: the small molecule pathway database. Nucleic Acids Res., 2010 38, D480-D487.
180. Pico, A.R.; Kelder, T.; van Iersel, M.P.; Hanspers, K.; Conklin, B.R.; Evelo, C. WikiPathways: pathway editing for the people. PLoS Biol., 2008, 6(7), e184.
181. Kankainen, M.; Gopalacharyulu, P.; Holm, L.; Orešič, M. MPEA-metabolite pathway enrichment analysis. Bioinformatics, 2011, 27(13), 1878-1879.